Get Articles Daily from StraightStocks - Enter Email Address


  • National Debt Clock




Bayer’s Cancer Drug Shows Benefit – Analyst Blog

Source: http://www.zacks.com/stock/news/25107/Bayer%27s+Cancer+Drug+Shows+Benefit+-+Analyst+Blog
 Posted on Wednesday, September 23rd, 2009 | In Investing Lessons, Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -

In a positive development, Bayer (BAYRY.PK) released encouraging results from a phase II trial of regorafenib in patients with metastatic renal cell carcinoma (RCC), a type of kidney cancer. The phase II trial was carried out on 49 previously untreated patients whose tumors could not be removed surgically or had started spreading.

The trial met its primary endpoint, which was to evaluate response rate according to the Response Evaluation Criteria in Solid Tumors (RECIST). It was observed that 31% of patients experienced a confirmed partial response (PR) whereas 50% of patients experienced stable disease (SD). In addition, the data showed an estimated median progression-free survival of 8.3 months.

The data were presented in an oral session at the joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology (ECCO 15 – 34th ESMO) at Berlin . The promising results of regorafenib show its potential as a first-line treatment option for patients with advanced RCC. Following encouraging results, Bayer intends to begin phase III trials of the drug.

Earlier in May 2009, Onyx Pharmaceuticals (ONXX) sued Bayer regarding the rights to regorafenib. Both the companies co-developed Nexavar, for the treatment of liver cancer and advanced kidney cancer.

With the molecular structure of both the drugs being similar except for one atom, Onyx filed a complaint claiming its right to the drug. It alleges that the drug should be treated under the collaboration agreement while Bayer claims its sole rights.

Nexavar is one of Bayer’s new drugs with huge potential which recorded sales of €147 million during the second quarter, up by 36%. Following positive results of regorafenib, stakes are quite high for both the companies.
Read the full analyst report on “BAYRY.PK”
Read the full analyst report on “ONXX”
Zacks Investment Research

Last 5 posts by Zacks Market Commentaries
About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries

No Responses to “Bayer’s Cancer Drug Shows Benefit – Analyst Blog”

  1. Bayer’s Cancer Drug Shows Benefit – Analyst Blog Says:
    September 23rd, 2009 at 5:20 pm

    [...] Here is the original: Bayer’s Cancer Drug Shows Benefit – Analyst Blog [...]

Leave a Reply

Name

Email (kept private)

Website












No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.